Emanuel Petricoin, III, Co-Director, Center for Applied Proteomics and Molecular Medicine (CAPMM), received $280,696 from Gateway for Cancer Research for: “Discovery of Protein Biomarkers for Response Prediction to Novel Phase II Targeted Therapy Agents for Stage II/III Breast Cancer Patients in the ISPY2 TRIAL.” This funding began in October 2020 and will end in late September 2022.
###
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.